On July 17, Kelun-Biotech declined 3.25% in regular trading, trading at 500.5 HKD/share, with turnover of HKD 197 million.

The decline represents a continuation of profit-taking following the company's announcement on July 15 that its core TROP2 ADC sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab met the primary endpoint in a Phase III study for first-line treatment of PD-L1-negative advanced non-squamous NSCLC. The stock surged over 11% on that day but has since retreated for two consecutive sessions as investors locked in gains.

The broader biotechnology sector experienced significant selling pressure, amplifying the pullback. Within the sector, AKESO fell 7.81%, 3SBIO fell 6.64%, Remegen fell 6.41%, Innovent Bio fell 2.02%, and BeiGene fell 1.99%. Goldman Sachs had raised its target price to HKD 582.95 on July 16 while maintaining a Buy rating, citing increased probability of success for the Lung06 study from 81% to 90%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)